According to a recent report by Fact.MR, the global lung cancer diagnostics market is anticipated to register 7.3% CAGR throughout the forecast period 2017 to 2022. Growth of the global lung cancer diagnostics market is mainly attributed to surging developments in the lung cancer-specific biomarkers. Diagnostic tools, such as these, will facilitate personalized treatment approach for lung malignancies. Numerous biomarkers are in the research pipeline. Epigenomics AG has launched a new test which is based on blood by utilizing DNA methylation biomarkers, and their developments are in process. Initial results of these tests have guaranteed early diagnosis of lung cancer. These incidences are most likely to increase demand for diagnosis of lung cancer across the globe. Request Sample Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=49 The growth of the global market for lung cancer diagnostics is primarily attributed to increasing developments in...